Meta-analysis of Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments

English version České info

Autism spectrum disorders (ASD) are a heterogeneous group of neurodevelopmental disorders. Mutations altering genes involved in the junction between brain cells have been repeatedly associated in ASD. For example, SHANK1, SHANK2 and SHANK3 emerged as one family of genes that are associated with ASD. However, little was known about the number of patients carrying these mutations and the clinical outcome. Here, we performed a new genetic screen of SHANK mutations and these results were analyzed in combination with those of the literature. In summary, SHANK mutations account for ∼1% of patients with ASD and were detected in the whole spectrum of autism with a gradient of severity in cognitive impairment: mutations in SHANK1 were rare (0.04%) and present in males with normal IQ and autism; mutations in SHANK2 were present in 0.17% of patients with ASD and mild intellectual disability; mutations in SHANK3 were present in 0.69% of patients with ASD and up to 2.12% of the cases with moderate to profound intellectual disability. Given the high frequency and impact of SHANK3 mutations in individuals with ASD and intellectual disability—more than 1 in 50—this gene should be screened for mutations in clinical practice.

Vyšlo v časopise: Meta-analysis of Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments. PLoS Genet 10(9): e32767. doi:10.1371/journal.pgen.1004580
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004580

Souhrn

Zdroje

1. GeschwindDH (2009) Advances in autism. Annu Rev Med 60: 367–380.

2. HuguetG, EyE, BourgeronT (2013) The Genetic Landscapes of Autism Spectrum Disorders. Annu Rev Genomics Hum Genet 14: 191–213.

3. BetancurC (2011) Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting. Brain Res 1380: 42–77.

4. ToroR, KonyukhM, DelormeR, LeblondC, ChasteP, et al. (2010) Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet 26: 363–372.

5. JamainS, QuachH, BetancurC, RastamM, ColineauxC, et al. (2003) Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34: 27–29.

6. DurandCM, BetancurC, BoeckersTM, BockmannJ, ChasteP, et al. (2007) Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 39: 25–27.

7. SzatmariP, PatersonAD, ZwaigenbaumL, RobertsW, BrianJ, et al. (2007) Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 39: 319–328.

8. PintoD, PagnamentaAT, KleiL, AnneyR, MericoD, et al. (2010) Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466: 368–372.

9. SandersSJ, Ercan-SencicekAG, HusV, LuoR, MurthaMT, et al. (2011) Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70: 863–885.

10. CooperGM, CoeBP, GirirajanS, RosenfeldJA, VuTH, et al. (2011) A copy number variation morbidity map of developmental delay. Nat Genet 43: 838–846.

11. SudhofTC (2008) Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455: 903–911.

12. GrabruckerAM, SchmeisserMJ, SchoenM, BoeckersTM (2011) Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. Trends Cell Biol 21: 594–603.

13. MoessnerR, MarshallCR, SutcliffeJS, SkaugJ, PintoD, et al. (2007) Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 81: 1289–1297.

14. BerkelS, MarshallCR, WeissB, HoweJ, RoethR, et al. (2010) Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 42: 489–491.

15. PhelanK, McDermidHE (2012) The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome). Mol Syndromol 2: 186–201.

16. GauthierJ, SpiegelmanD, PitonA, LafreniereRG, LaurentS, et al. (2009) Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 150B: 421–424.

17. BoccutoL, LauriM, SarasuaSM, SkinnerCD, BuccellaD, et al. (2012) Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet 3: 310–316.

18. LeblondCS, HeinrichJ, DelormeR, ProepperC, BetancurC, et al. (2012) Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet 8: e1002521.

19. SatoD, LionelAC, LeblondCS, PrasadA, PintoD, et al. (2012) SHANK1 Deletions in Males with Autism Spectrum Disorder. Am J Hum Genet 90: 879–887.

20. SooryaL, KolevzonA, ZweifachJ, LimT, DobryY, et al. (2013) Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Mol Autism 4: 18.

21. BonagliaMC, GiordaR, BeriS, De AgostiniC, NovaraF, et al. (2011) Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome. PLoS Genet 7: e1002173.

22. BetancurC, BuxbaumJD (2013) SHANK3 haploinsufficiency: a “common” but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. Mol Autism 4: 17.

23. JiangYH, EhlersMD (2013) Modeling autism by SHANK gene mutations in mice. Neuron 78: 8–27.

24. HungAY, FutaiK, SalaC, ValtschanoffJG, RyuJ, et al. (2008) Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci 28: 1697–1708.

25. WohrM, RoulletFI, HungAY, ShengM, CrawleyJN (2011) Communication impairments in mice lacking Shank1: reduced levels of ultrasonic vocalizations and scent marking behavior. PLoS One 6: e20631.

26. SchmeisserMJ, EyE, WegenerS, BockmannJ, StempelAV, et al. (2012) Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature 486: 256–260.

27. WonH, LeeH-R, GeeHY, MahW, KimJ-I, et al. (2012) Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486: 261–265.

28. PecaJ, FelicianoC, TingJT, WangW, WellsMF, et al. (2011) Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472: 437–442.

29. YangM, BozdagiO, ScattoniML, WoehrM, RoulletFI, et al. (2012) Reduced Excitatory Neurotransmission and Mild Autism-Relevant Phenotypes in Adolescent Shank3 Null Mutant Mice. Journal of Neuroscience 32: 6525–6541.

30. WangX, McCoyPA, RodriguizRM, PanY, JeHS, et al. (2011) Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet 20: 3093–3108.

31. Schluth-BolardC, LabalmeA, CordierMP, TillM, NadeauG, et al. (2013) Breakpoint mapping by next generation sequencing reveals causative gene disruption in patients carrying apparently balanced chromosome rearrangements with intellectual deficiency and/or congenital malformations. J Med Genet 50: 144–150.

32. SandersSJ, MurthaMT, GuptaAR, MurdochJD, RaubesonMJ, et al. (2012) De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485: 237–241.

33. WischmeijerA, MaginiP, GiordaR, GnoliM, CicconeR, et al. (2011) Olfactory Receptor-Related Duplicons Mediate a Microdeletion at 11q13.2q13.4 Associated with a Syndromic Phenotype. Mol Syndromol 1: 176–184.

34. GlessnerJT, WangK, CaiG, KorvatskaO, KimCE, et al. (2009) Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459: 569–573.

35. SchaafCP, SaboA, SakaiY, CrosbyJ, MuznyD, et al. (2011) Oligogenic heterozygosity in individuals with high-functioning autism spectrum disorders. Hum Mol Genet 20: 3366–3375.

36. O'RoakBJ, VivesL, GirirajanS, KarakocE, KrummN, et al. (2012) Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485: 246–250.

37. NealeBM, KouY, LiuL, Ma'ayanA, SamochaKE, et al. (2012) Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485: 242–245.

38. KrummN, O'RoakBJ, ShendureJ, EichlerEE (2014) A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci 37: 95–105.

39. GuilmatreA, HuguetG, DelormeR, BourgeronT (2013) The emerging role of SHANK genes in neuropsychiatric disorders. Dev Neurobiol 74 (2) 113–22.

40. ShcheglovitovA, ShcheglovitovaO, YazawaM, PortmannT, ShuR, et al. (2013) SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 503: 267–271.

41. DelormeR, EyE, ToroR, LeboyerM, GillbergC, et al. (2013) Progress toward treatments for synaptic defects in autism. Nat Med 19: 685–694.

42. DurandCM, PerroyJ, LollF, PerraisD, FagniL, et al. (2011) SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 17: 71–84.

43. AronsMH, ThynneCJ, GrabruckerAM, LiD, SchoenM, et al. (2012) Autism-Associated Mutations in ProSAP2/Shank3 Impair Synaptic Transmission and Neurexin-Neuroligin-Mediated Transsynaptic Signaling. J Neurosci 32: 14966–14978.

44. BerkelS, TangW, TrevinoM, VogtM, ObenhausHA, et al. (2011) Inherited and de novo SHANK2 variants associated with autism spectrum disorder impair neuronal morphogenesis and physiology. Hum Mol Genet 21: 344–357.

45. DenayerA, Van EschH, de RavelT, FrijnsJP, Van BuggenhoutG, et al. (2012) Neuropsychopathology in 7 Patients with the 22q13 Deletion Syndrome: Presence of Bipolar Disorder and Progressive Loss of Skills. Mol Syndromol 3: 14–20.

46. ChilianB, AbdollahpourH, BierhalsT, HaltrichI, FeketeG, et al. (2013) Dysfunction of SHANK2 and CHRNA7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci. Clin Genet 84 (6) 560–5 doi: 10.1111/cge.12105

47. GauthierJ, ChampagneN, LafreniereRG, XiongL, SpiegelmanD, et al. (2010) De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A 107: 7863–7868.

48. LordC, RutterM, Le CouteurA (1994) Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24: 659–685.

49. LordC, RisiS, LambrechtL, CookEHJr, LeventhalBL, et al. (2000) The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30: 205–223.

50. WingL, LeekamSR, LibbySJ, GouldJ, LarcombeM (2002) The Diagnostic Interview for Social and Communication Disorders: background, inter-rater reliability and clinical use. J Child Psychol Psychiatry 43: 307–325.

51. SebatJ, LakshmiB, MalhotraD, TrogeJ, Lese-MartinC, et al. (2007) Strong association of de novo copy number mutations with autism. Science 316: 445–449.

52. MarshallCR, NoorA, VincentJB, LionelAC, FeukL, et al. (2008) Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82: 477–488.

53. BremerA, GiacobiniM, NordenskjoldM, Brondum-NielsenK, MansouriM, et al. (2009) Screening for copy number alterations in loci associated with autism spectrum disorders by two-color multiplex ligation-dependent probe amplification. Am J Med Genet B Neuropsychiatr Genet 153B: 280–285.

54. ClopperCJ, PearsonES (1934) The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial. Biometrika 26: 404–413.

55. HigginsJP, ThompsonSG, DeeksJJ, AltmanDG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.

56. FriedrichJO, AdhikariNK, BeyeneJ (2007) Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 7: 5.

57. LanePW (2013) Meta-analysis of incidence of rare events. Stat Methods Med Res 22: 117–132.